Efficacy and Safety of Vespireit, Prolonged-release Tablets, in Patients With Autonomic Dysfunction Syndrome Accompanied by Functional Vertigo

PHASE4RecruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

January 24, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
VertigoAutonomic Dysfunction
Interventions
DRUG

Vespireit

Buspirone

DRUG

Arlevert

Dimenhydrinate + Cinnarizine

Trial Locations (4)

109263

RECRUITING

"State Budgetary Institution of Healthcare of the City of Moscow V.P. Demikhov City Clinical Hospital of the Department of Healthcare of the City of Moscow", Moscow

214025

RECRUITING

"Private Healthcare Institution Clinical Hospital RZD-Medicine of the city of Smolensk", Smolensk

241050

RECRUITING

Central Clinic LLC, Bryansk

610027

RECRUITING

"Federal State Budgetary Educational Institution of Higher Education Kirov State Medical University of the Ministry of Healthcare of the Russian Federation", Kirov

All Listed Sponsors
lead

Valenta Pharm JSC

INDUSTRY